Your browser doesn't support javascript.
loading
The importance of endpoint selection: How effective does a drug need to be for success in a clinical trial of a possible Alzheimer's disease treatment?
Evans, Stephanie; McRae-McKee, Kevin; Wong, Mei Mei; Hadjichrysanthou, Christoforos; De Wolf, Frank; Anderson, Roy.
Affiliation
  • Evans S; Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, London, UK. s.evans@imperial.ac.uk.
  • McRae-McKee K; Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, London, UK.
  • Wong MM; Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, London, UK.
  • Hadjichrysanthou C; Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, London, UK.
  • De Wolf F; Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, London, UK.
  • Anderson R; Janssen Prevention Center, Leiden, The Netherlands.
Eur J Epidemiol ; 33(7): 635-644, 2018 Jul.
Article in En | MEDLINE | ID: mdl-29572656
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Brain / Cognition / Alzheimer Disease / Neuroimaging Limits: Humans Language: En Journal: Eur J Epidemiol Journal subject: EPIDEMIOLOGIA Year: 2018 Type: Article Affiliation country: United kingdom
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Brain / Cognition / Alzheimer Disease / Neuroimaging Limits: Humans Language: En Journal: Eur J Epidemiol Journal subject: EPIDEMIOLOGIA Year: 2018 Type: Article Affiliation country: United kingdom